Company: ABBV
Filing Date: 2025-03-10
Form Type: PRE 14A
Source: 0001558370-25-002603
Chunk: 74

Company: AbbVie Inc.
Filing Date: 2025-03-10
Form: PRE 14A
Chunk 74
---
-|:--|:--|----------------:|:--|:--|----------------:|:--|:--|----------------:|:--|:--|:----------------|:--|:--|----------------:|
| 2024 | ​ | ​ | See footnote (c) | ​ | $ |         990,295 | ​ | $ |        -990,295 | ​ | $ |         432,919 | ​ | $ | N/A             | ​ | $ |         432,919 |

| (e) | Cumulative TSR is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between AbbVie’s share price at the end and the beginning of the measurement period by AbbVie's share price at the beginning of the measurement period. |

| (f) | Represents the weighted peer group TSR, weighted according to the respective companies’ stock market capitalization at the beginning of each period for which a return is indicated. The peer group used for this purpose is the NYSE Arca Pharmaceutical Index, our peer group used for purposes of Item 201(e) of Regulation S-K. |

| (g) | As required by Item 402(v) of Regulation S-K, AbbVie has determined that adjusted diluted EPS is the Company Selected Measure, as it is the most important financial performance measure (that is not otherwise required to be disclosed in the table) used to link compensation actually paid to AbbVie’s NEOs to company performance for the most recently completed fiscal year.  Adjusted diluted EPS is a non-GAAP measure that represents diluted earnings per share adjusted to exclude certain specified items, as described in Appendix B. Adjusted diluted EPS includes an unfavorable impact related to acquired IPR&D, milestone and/or Calico-related expenses of $1.52 in 2024, $0.42 in 2023, $0.39 in 2022, $0.90 in 2021 and $0.81 in 2020. |

66 | 2025 Proxy Statement

| ​ | ​                      |
| ​ | EXECUTIVE COMPENSATION |

Comparative Analysis of the Pay versus Performance Table AbbVie’s compensation program is designed to attract and retain executives whose talents and contributions sustain long-term growth by aligning their interests with the drivers of stockholder returns and supporting their achievement of AbbVie’s primary business goals. AbbVie considers several performance measures to ensure